Buprenorphine brand name
Pro Research Analysisby 
Searched over 200M research papers
Buprenorphine Brand Name: Subutex and Suboxone
Introduction to Buprenorphine Brand Names
Buprenorphine, a medication used for opioid maintenance treatment and pain relief, is available under several brand names. The most notable among these are Subutex and Suboxone. Subutex contains buprenorphine alone, while Suboxone combines buprenorphine with naloxone to deter misuse 35.
Preference for Brand-Name Buprenorphine
Severity of Addiction and Brand Preference
Research indicates that patients with more severe addiction levels tend to prefer brand-name buprenorphine over generic versions. A study conducted in France found that patients using the brand-name form of buprenorphine, after having experience with the generic form, exhibited higher addiction severity and required higher dosages. These patients also had higher alcohol consumption and were more likely to use psychotropic substances daily . Another study confirmed that negative perceptions of opioid maintenance treatment (OMT) are linked to a preference for brand-name buprenorphine, suggesting that patients view the brand-name product as more effective or trustworthy .
Impact of Switching from Brand to Generic
Patients who switch from brand-name Suboxone to generic versions often report withdrawal symptoms and cravings, indicating a preference for the brand-name formulation. A case series study showed that 37.5% of patients experienced withdrawal symptoms after switching to generic versions, and all preferred the brand-name Suboxone over the generics .
Market and Regulatory Factors
Delayed Generic Entry
The widespread use of brand-name buprenorphine formulations, particularly Suboxone, has led to significant costs for Medicaid. This is partly due to delays in the availability of generic versions caused by market and regulatory factors. For instance, the generic tablet formulation faced a 9-year delay due to Orphan Drug Act exclusivity and other regulatory hurdles, while the film formulation faced a 6-year delay due to patent litigation 47.
Utilization and Spending Trends
Between 2002 and 2018, brand-name buprenorphine-naloxone formulations were dispensed and reimbursed significantly more than their generic counterparts. Suboxone, in particular, was dispensed 2.7 times more and reimbursed 4.4 times more than all other formulations combined .
Clinical Considerations
Prescribing Patterns
Buprenorphine/naloxone, under the brand name Suboxone, is primarily prescribed for opioid use disorder (OUD). However, it is also prescribed for pain management, especially for patients at high risk of OUD. The number of patients with a buprenorphine/naloxone prescription increased substantially from 2011 to 2015, reflecting its growing acceptance and utilization in clinical practice .
Conclusion
The preference for brand-name buprenorphine, particularly Subutex and Suboxone, is influenced by the severity of addiction, patient perceptions, and regulatory factors. While brand-name formulations are more costly, they are often preferred by patients due to perceived efficacy and fewer withdrawal symptoms. Understanding these preferences and the factors influencing them is crucial for optimizing treatment strategies for opioid use disorder.
Sources and full results
Most relevant research papers on this topic